Cell Medica, asserted the appointment of Kevin S. Boyle, Sr as the Chief Financial Officer, based in Houston, TX. Kevin S. Boyle ushers on board 20 years of financial and capital markets experience. He is accountable for ground-breaking Clinical Trials to investigate cancer treatments incorporating Cell Medica’s innovative chimeric antibody receptor (CAR) and engineered T cell receptor (TCR) cell therapies.
As far as his prior stints are concerned Kevin has held senior finance roles at both NASDAQ-listed and private equity backed companies. He is an accomplished capital markets professional with strong banking relationships cultivated by raising over $2.0 billion in equity and debt capital. At Cell Medica, Kevin will play a lead role in both corporate strategy and financial planning as the Company progresses with an exciting pipeline of CAR and TCR products in both the US and Europe.
Gregg Sando, CEO Cell Medica, commented: “We look forward to Kevin joining Cell Medica as we prepare for significant growth in our CAR and TCR development activities. His US capital markets experience and proven deal-making acumen will complement the capabilities of our current senior management team and help us realise the immense potential of our cell-based immunotherapies for the treatment of cancer patients.”